Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BEAM – Beam Therapeutics Inc.

Beam Therapeutics Inc.
BEAM
$18.58
Name : Beam Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,867,846,400.00
EPSttm : -4.61
finviz dynamic chart for BEAM
Beam Therapeutics Inc.
$18.58
9.26%
$1.58

Float Short %

23.26

Margin Of Safety %

Put/Call OI Ratio

2.2

EPS Next Q Diff

0.16

EPS Last/This Y

0.08

EPS This/Next Y

0.02

Price

18.58

Target Price

43.44

Analyst Recom

1.39

Performance Q

-34.78

Relative Volume

1.64

Beta

2.08

Ticker: BEAM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08BEAM17.381.780.4734855
2025-05-09BEAM17.411.780.0834883
2025-05-12BEAM18.751.650.2735906
2025-05-13BEAM18.061.660.0535835
2025-05-14BEAM17.231.650.2335903
2025-05-15BEAM17.231.620.4936280
2025-05-16BEAM17.891.570.3736112
2025-05-19BEAM17.652.500.3130264
2025-05-20BEAM17.742.440.1430599
2025-05-21BEAM17.242.380.0630874
2025-05-22BEAM17.252.280.3431303
2025-05-23BEAM16.832.231.1331669
2025-05-27BEAM17.022.231.1231729
2025-05-28BEAM16.872.230.0531730
2025-05-29BEAM16.322.200.5231862
2025-05-30BEAM15.812.190.1831960
2025-06-02BEAM16.172.150.1832166
2025-06-03BEAM16.892.170.0432121
2025-06-04BEAM17.152.210.1231951
2025-06-05BEAM172.190.6632010
2025-06-06BEAM18.582.200.1032093
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08BEAM17.21-3.6- -4.81
2025-05-09BEAM17.410.2- -4.55
2025-05-12BEAM18.240.2- -4.55
2025-05-13BEAM18.051.2- -4.54
2025-05-14BEAM17.242.9- -4.54
2025-05-15BEAM17.242.9- -4.54
2025-05-16BEAM17.882.9- -4.54
2025-05-19BEAM17.662.9- -4.54
2025-05-20BEAM17.742.9- -4.54
2025-05-21BEAM17.232.9- -4.54
2025-05-22BEAM17.242.9- -4.54
2025-05-23BEAM16.832.9- -4.54
2025-05-27BEAM17.032.9- -4.54
2025-05-28BEAM16.872.9- -4.54
2025-05-29BEAM16.312.9- -4.54
2025-05-30BEAM15.832.9- -4.54
2025-06-02BEAM16.182.9- -4.54
2025-06-03BEAM16.882.9- -4.54
2025-06-04BEAM17.152.9- -4.54
2025-06-05BEAM17.002.9- -4.54
2025-06-06BEAM18.582.9- -4.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08BEAM-1.203.0421.90
2025-05-09BEAM-0.863.0421.90
2025-05-12BEAM-0.863.9922.40
2025-05-13BEAM-0.863.9922.40
2025-05-14BEAM-0.863.9922.40
2025-05-15BEAM-1.023.9921.82
2025-05-16BEAM-1.023.9921.82
2025-05-19BEAM-1.0215.2622.02
2025-05-20BEAM-0.9515.2622.02
2025-05-21BEAM-0.9515.2622.02
2025-05-22BEAM-0.9515.2622.02
2025-05-23BEAM-0.9515.2622.03
2025-05-27BEAM-0.9527.7321.49
2025-05-28BEAM-1.1427.7323.26
2025-05-29BEAM-1.1427.7323.26
2025-05-30BEAM-1.1427.7323.26
2025-06-02BEAM-1.1428.1423.26
2025-06-03BEAM-1.1428.1423.26
2025-06-04BEAM-1.1428.1423.26
2025-06-05BEAM-1.1428.1423.26
2025-06-06BEAM-1.1428.1423.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.24

Avg. EPS Est. Current Quarter

-1.08

Avg. EPS Est. Next Quarter

-1.08

Insider Transactions

-1.14

Institutional Transactions

28.14

Beta

2.08

Average Sales Estimate Current Quarter

13

Average Sales Estimate Next Quarter

14

Fair Value

Quality Score

20

Growth Score

32

Sentiment Score

81

Actual DrawDown %

86.6

Max Drawdown 5-Year %

-89.1

Target Price

43.44

P/E

Forward P/E

PEG

P/S

29.38

P/B

1.66

P/Free Cash Flow

EPS

-4.61

Average EPS Est. Cur. Y​

-4.5

EPS Next Y. (Est.)

-4.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-609.24

Relative Volume

1.64

Return on Equity vs Sector %

-58.5

Return on Equity vs Industry %

-40.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.16

EBIT Estimation

Beam Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 393
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
stock quote shares BEAM – Beam Therapeutics Inc. Stock Price stock today
news today BEAM – Beam Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BEAM – Beam Therapeutics Inc. yahoo finance google finance
stock history BEAM – Beam Therapeutics Inc. invest stock market
stock prices BEAM premarket after hours
ticker BEAM fair value insiders trading